These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31439831)

  • 1. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.
    Wilson R; Bossong MG; Appiah-Kusi E; Petros N; Brammer M; Perez J; Allen P; McGuire P; Bhattacharyya S
    Transl Psychiatry; 2019 Aug; 9(1):203. PubMed ID: 31439831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
    Gunasekera B; Wilson R; O'Neill A; Blest-Hopley G; O'Daly O; Bhattacharyya S
    Psychol Med; 2023 Jul; 53(10):4732-4741. PubMed ID: 35775365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers.
    Lawn W; Hill J; Hindocha C; Yim J; Yamamori Y; Jones G; Walker H; Green SF; Wall MB; Howes OD; Curran HV; Freeman TP; Bloomfield MA
    J Psychopharmacol; 2020 Sep; 34(9):969-980. PubMed ID: 32755273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
    Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
    JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of motivational salience processing during the early stages of psychosis.
    Smieskova R; Roiser JP; Chaddock CA; Schmidt A; Harrisberger F; Bendfeldt K; Simon A; Walter A; Fusar-Poli P; McGuire PK; Lang UE; Riecher-Rössler A; Borgwardt S
    Schizophr Res; 2015 Aug; 166(1-3):17-23. PubMed ID: 25999039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
    Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.
    Bhattacharyya S; Crippa JA; Allen P; Martin-Santos R; Borgwardt S; Fusar-Poli P; Rubia K; Kambeitz J; O'Carroll C; Seal ML; Giampietro V; Brammer M; Zuardi AW; Atakan Z; McGuire PK
    Arch Gen Psychiatry; 2012 Jan; 69(1):27-36. PubMed ID: 22213786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
    Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
    Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis.
    Schmidt A; Palaniyappan L; Smieskova R; Simon A; Riecher-Rössler A; Lang UE; Fusar-Poli P; McGuire P; Borgwardt SJ
    J Psychiatry Neurosci; 2016 Oct; 41(6):367-376. PubMed ID: 26854756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reward anticipation in individuals with subclinical psychotic experiences: A functional MRI approach.
    Michielse S; Lange I; Bakker J; Goossens L; Verhagen S; Papalini S; Wichers M; Lieverse R; Schruers K; van Amelsvoort T; van Os J; Murray GK; Marcelis M
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1374-1385. PubMed ID: 31685359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reward disturbances in antipsychotic-naïve patients with first-episode psychosis and their association to glutamate levels.
    Tangmose K; Rostrup E; Bojesen KB; Sigvard A; Jessen K; Johansen LB; Glenthøj BY; Nielsen MØ
    Psychol Med; 2023 Mar; 53(4):1629-1638. PubMed ID: 37010221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
    Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
    Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
    Dixon T; Cadenhead KS
    Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study.
    Knolle F; Ermakova AO; Justicia A; Fletcher PC; Bunzeck N; Düzel E; Murray GK
    Transl Psychiatry; 2018 Sep; 8(1):196. PubMed ID: 30242202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
    Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
    Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy.
    Allendorfer JB; Nenert R; Bebin EM; Gaston TE; Grayson LE; Hernando KA; Houston JT; Hansen B; Szaflarski JP
    Epilepsy Behav; 2019 Jul; 96():114-121. PubMed ID: 31129526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol modulation of hippocampal glutamate in early psychosis.
    O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
    J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
    Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV
    J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition.
    Borgwardt SJ; Allen P; Bhattacharyya S; Fusar-Poli P; Crippa JA; Seal ML; Fraccaro V; Atakan Z; Martin-Santos R; O'Carroll C; Rubia K; McGuire PK
    Biol Psychiatry; 2008 Dec; 64(11):966-73. PubMed ID: 18589404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis.
    Schmidt A; Antoniades M; Allen P; Egerton A; Chaddock CA; Borgwardt S; Fusar-Poli P; Roiser JP; Howes O; McGuire P
    Psychol Med; 2017 Jan; 47(2):243-254. PubMed ID: 27697078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.